口服铁与静脉注射蔗糖铁在肾性贫血中的疗效观察

目的 比较口服铁剂多糖铁复合物（红源达）、静脉铁剂蔗糖铁（森铁能）分别与重组人红细胞生成素（EPO）联合使用，治疗伴有肾性贫血的维持性血液透析患者的临床有效性。方法 病例来自2016年6月至2017年4月濮阳市人民医院肾病科收治的144例维持性血液透析肾病患者；144例患者分为口服组和静脉组；口服组（76例）患者服用多糖铁复合物，每次150 mg，每日2次；餐前1h或餐后2h服用，总疗程8周。静脉组（68例）：将100 mg蔗糖铁稀释于100 mL生理盐水中，前4周每周2次，每次100 mg；以后每周1次，每次100 mg。结果 经χ²检验分析显示，口服组与静脉组间性别组成无显著差异，没有统计学意义，P>0.05 ；两治疗组的独立样本t检验显示，年龄、体重、EPO剂量等在两组间的差异无统计学意义，P>0.05。两组间各项指标在治疗前均无统计学差异(均P>0.05)；治疗3个月后，两组分别与治疗前相比，Hb、HCT、MCV、MCH、MCHC、FER水平均显著改善(均PP＞0.05）；静脉组Hb、FER水平明显高于口服组，但其值均在正常范围，差异无统计学意义(均P＞0.05)。结论 口服多糖铁复合物与静脉铁剂蔗糖铁在纠正透析患者肾性贫血时疗效相当。

Observation of curactive effect of oral iron and intravenous iron sucrosein renal anemia

Objective Comparison of oral iron polysaccharide iron complex (red source of), intravenous iron sucrose iron (iron can) respectively with recombinant human erythropoietin (EPO) joint use, treatment of maintenance hemodialysis patients with renal anemia clinical effectiveness. Methods The cases were from the 144 patients who received kidney disease from June 2016 to April 2017 at the people''s hospital of puyang. The 144 patients were divided into oral and intravenous groups; Oral group (76) patients were given a polysaccharide complex,150mg per day, two times a day; 1 h or 2h after meal. Total treatment for 8 weeks. Venous group (68) : dilute 100mg of sucrose iron into 100 ml of saline water, 2 times per week in the first 4 weeks, 100mg per week; Once a week, 100 mg per time.Results According to the chi 2 test analysis, there was no statistical difference between the oral group and the vein group, P>0.05.By two independent sample t-test, age, weight, EPO dose, hemoglobin, red blood cells deposited, ferritin in no statistically significant differences between the two groups, P>0.05).Before the treatment, the differences between the two groups were statistically significant (both P>0.05).After three months of treatment, both groups were significantly improved in Hb, HCT, MCV, MCH, MCHC, and FER, respectively compared to the treatment before treatment.After 3 months of treatment, there was no significant difference between the HCT, MCV, MCH, MCHC and the oral group (all P>0.05).The Hb and FER levels were significantly higher than the oral group, but their value was in the normal range, and the difference was not statistically significant (both P>0.05).Conclusion Oral polysaccharide iron complex and venous iron sucrose iron are effective in correcting renal anemia in dialysis patients.